Serving Our Partners
Pharmaron is proud to partner with organizations who are shaping the future of the healthcare industry. For every project we successfully complete, we know it helps our partners move one step closer to their goal. These goals impact millions of people, as it means new life- saving medicines are discovered. On April 1, IFM Therapeutics announced a deal where Novartis acquires their subsidiary, IFM Tre’s portfolio of NLPR3 antagonists, which consists of one clinical and two pre-clinical programs.
IFM has been a partner with Pharmaron since 2015, and during this period our teams have had the privilege of providing a broad range of services which includes medicinal & process chemistry, DMPK, in vitro biology and GMP manufacturing.
Learn more about our small molecule services
